Biotech Values

[DewDiligence]

“Xu notes Johnson & Johnson (NYSE: JNJ), Boehringer Ingelheim, GlaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) are all possible suitors for the acquisition…” Pretty good call by this analyst, lol

I agree with the LOL part of your statement. The analyst didn’t mention Roche, the actual acquirer. Moreover, it was dumb of the analyst to include NVS, which has abandoned the HCV arena, as a potential suitor for a company whose only assets are drug candidates for HCV.

The timing of the analyst’s report—as opposed to the content of the prediction—can probably be explained by a leak at ANDS or the investment banker working on the deal.